

## Original Article

# Pathogen distribution and drug resistance in a burn ward: a three-year retrospective analysis of a single center in China

Hanghui Cen<sup>1</sup>, Zhenbo Wu<sup>2</sup>, Fan Wang<sup>1</sup>, Chunmao Han<sup>1</sup>

Departments of <sup>1</sup>Burns, <sup>2</sup>Hospital Infection Management Section, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou 310000, Zhejiang, China

Received March 2, 2015; Accepted September 17, 2015; Epub October 15, 2015; Published October 30, 2015

**Abstract:** To investigate the spread of multiple-resistant strain in a burn ward to inform clinical administration of antibiotic drugs, burn wound treatment and decision-making for infection control. A 3-year retrospective analysis was conducted. Specimens from wounds, blood, catheter, sputum, urine and stool collected from inpatients of the Second Affiliated Hospital of Zhejiang University of Medicine between January 1, 2011 and December 31, 2013 were cultured and strains were identified by automatic bacteria analysis. Sensitivity to 30 commonly used antibiotics was assessed by K-B disk diffusion. A total of 2212 strains of pathogenic bacteria or fungi were isolated (33.9% Gram-positive and 52.7% Gram-negative bacteria and 13.4% fungi), including 1466 from wound extracts, 128 from blood culture, 335 from urine culture, 5 from stool culture, 153 from sputum culture and 125 from catheters. The most frequently detected pathogens in wound secretions were *Staphylococcus aureus*, *Pseudomonas aeruginosa* and *Acinetobacter baumannii*. The Gram-positive bacteria *Staphylococcus epidermidis*, *Enterococcus faecalis* and *Enterococcus faecium*, and the Gram-negative bacteria *Escherichia coli*, *Klebsiella pneumoniae*, *Enterobacter cloacae*, *Stenotrophomonas maltophilia*, *Proteus mirabilis* were also frequently detected. The most frequently detected strains of fungi were *Candida albicans*; *tropicalis*, *glabrata* and *parapsilosis*, and all were highly sensitive to itraconazole, fluconazole and voriconazole but resistant to ketoconazole. Attention should be paid to MRSA, multi-resistant *A. baumannii*, ESBL-producing enterobacteriaceae and Carbapenem-resistant *P. aeruginosa*. Understanding the distribution of bacterial infections in Chinese hospitals will be crucial to reduce hospital-acquired infection and drug resistance.

**Keywords:** Burns, wound infection, drug resistance, bacterial, drug resistance, fungal

## Introduction

Although rapid debridement of burn wounds and the application of topical and systemic antimicrobial agents can improve the outcome of burn injury, infection of burn wounds can become systemic, causing sepsis, and organ failure [1-3]. It is estimated that infection accounts for 75% of mortalities in patients with burn injuries [1, 4-8].

Although the initial burn wound is sterile, within 48 hours of injury disruption of the skin's mechanical integrity can allow bacteria typically found on the surface of the skin, and in sweat glands and hair follicles to colonize the wound. The presence of devitalized, avascularized tissue provides a favorable niche for microbial

growth, and later bacteria from the respiratory or digestive tract, hospital environment or healthcare workers can further contaminate the wound [4, 9, 10]. Immune suppression [11-15]; intestinal bacterial translocation; extended hospitalization and invasive diagnostic and therapeutic procedures including intubation and catheterization can all contribute to contamination of burn wounds and development systemic infection [16-21]. The emergence of multidrug resistant bacteria has also limited therapeutic options [22, 23] and increased mortality in burns patients [24].

Widespread use of antibiotics has been reported to hasten the spread of multidrug resistant nosocomial bacterial strains, predominantly *Staphylococcus aureus*, *Pseudomonas aerugi-*

*nosa* and *Acinetobacter baumannii* [3, 25-27]. Recent increases in the use of third-generation cephalosporins has also lead to emergence of new nosocomial infections in burn patients including the extended spectrum beta-lactamase (ESBL)-producing *Enterobacteriaceae* [17, 28, 29].

Excessive antibiotic drug use is a serious problem in China. In addition to widespread microbial resistance, hospital environments also contribute to hospital-acquired multiply drug resistant bacterial infections [30, 31]. Understanding the distribution of bacterial infections, and the extent of bacterial resistance to commonly used antibiotic drugs may inform development of procedures to reduce hospital-acquired infection and treatment guidelines designed to reduce the selection pressure for multiply-drug resistant pathogens.

In this study, we retrospectively characterized the pathogenic infections of 1942 inpatients of the burn ward of the second affiliated hospital of Zhejiang University of Medicine between January 1, 2011 and December 31, 2013. In total 2212 strains of pathogenic bacteria cultured from wound secretions, blood, catheter specimen, respiratory secretions, urine and stool were obtained for analysis and the distribution of bacterial species and antibiotic resistance was investigated.

### Materials and methods

#### Patients

Patients treated at the burn ward of Zhejiang University of Medicine between January 2011 and December 2013 were included in this retrospective analysis. The inclusion criteria were as follows: patients with burns extending over more than 10% of their skin surface; with III degree burns extending over more than 1% of their skin surface area; or with burn injuries of the head or face, or burns accompanied with inhalation injury. A total of 1942 patients were enrolled, ranging from 1 to 97 years of age, including 1395 men and 547 women.

After admission, the burn patients strictly adhered to hospital infection control procedures. For superficial II degree and deep II degree wounds antibiotic cream or silver ions were applied after debridement, and wounds

were dressed. Exposure therapy was applied to wounds of eschar III degree, which were then coated with PVP-I paste or silver sulfadiazine paste. For patients with superficial II degree wounds, dressing was changed the next day. Where possible patients with deep II degree received tangential excision treatment, and some patients received scab-dissolving treatment when dressings were changed. Where possible, patients with III degree wounds underwent excision of eschar, and skin grafting with protective xenoskin or allogenic skin.

Patients were discharged when wounds and skin donor sites had healed, and when underlying conditions such as hypertension and diabetes were controlled and improved.

After hospitalization, patients received routine prophylactic therapy with second to fourth generation cephalosporin antibiotics. Patients with burn area exceeding 30% received third to fourth generation cephalosporin antibiotics for triple treatment of Gram-positive and Gram-negative bacteria and fungi. Antibiotics were adjusted based on the susceptibility of pathogens.

#### Sample collection

Wound secretions were collected at patient admission and during hospitalization at least weekly. Respiratory secretions were collected from patients receiving preventive tracheotomy or ventilator support. During replacement of urinary catheters and deep vein catheter, samples were taken from this equipment. Bacterial cultures of these samples, and blood (two peripheral blood collected sites, or one peripheral blood intraductal blood, 2 sets of 4 bottles, with aerobic and anaerobic culture for each sample), urine and stool samples were made (2 sets of 4 bottles, with aerobic and anaerobic culture for each sample). For patients with suspected sepsis, temperature higher than 39°C or lower than 37°C, blood, urine, stool, phlegm and wound secretion culture was conducted for three consecutive days. Patients were treated according to the guidelines of the *Diagnostic Criteria for Infection after Burn Injury* (Chinese Journal of Burns, 2007) [32] until 2012. Thereafter patients were treated according to the revised guide, *Diagnostic Criteria and Treatment Guideline for Infection*

## Pathogen distribution and drug resistance in a burn ward

**Table 1.** Annual distribution of Gram-positive and negative bacteria and fungi detected in clinical samples

Year	Patients Tested	Samples Tested	Strains identified (n)	Gram-positive bacteria [n (%)]	Gram-negative bacteria [n (%)]	Fungi [n (%)]
2011	644	700	723	235 (32.5)	417 (57.7)*	71 (9.8)*
2012	665	732	750	257 (34.3)	349 (46.5)	144 (19.2)
2013	633	725	739	258 (34.9)	400 (54.1)*	81 (11)*
Total	1942	2157	2212	750 (33.9)	1166 (52.7)	296 (13.4)

\*P < 0.005 in comparison to 2012 data.

*of Burns and Guideline for Diagnosis, Prevention and Treatment of Invasive Fungal Infection after Burn Injury.*

Stool culture was only carried out when patients experienced diarrhea, other gastrointestinal symptoms or sepsis. Urine culture was regularly conducted in long-term catheterization or prior to catheter extraction. Conventional deep vein catheter indwelling was applied to critical patients, and swabs for culture were taken each time catheters were replaced, every 5-7 days.

Symptoms suggesting critical illness, or sepsis, include changes in color and smell of the wound secretions, granulation and increased bleeding in response to pressure, or inflammation of the wound and failure of the skin graft. Samples were taken more often from patients with more severe symptoms.

### *Species identification and antibiotic sensitivity*

Species identification and drug sensitivity were assessed by laboratory staff of the Second affiliated hospital of Zhejiang University of Medicine (certificated by United States Association of pathologists, CAP) using the K-B disk diffusion method drug sensitive test disks, culture medium and quality-control strains (*Escherichia coli* ATCC 25922, *Staphylococcus aureus* ATCC 25923, *P. aeruginosa* ATCC 27853) (Oxoid Corporation). The American Clinical and Laboratory Standards Institute (CLSI) standard was used to evaluate outcomes.

All specimens were inoculated in the appropriate culture medium and incubated at 35°C in accordance with their respective requirements for 18 to 20 hours. An API identification strip or Vitek-2 Compact automatic Bacteria analyz-

er (BioMerieux, France) was employed was used to identify strains. A 30 g cefoxitin disk was used to detect the Methicillin-resistant staphylococci. Methicillin resistance was detected in coagulase positive *Staphylococcus* where the diameter of the inhibition zone was  $\leq 21$  mm. Methicillin resistance was excluded in coagulase negative *Staphylococcus* where the diameter of the inhibition zone was  $\leq 24$  mm.

### *Statistical analysis*

WHONET 5.5 software and SPSS 19.0 (SPSS, Inc., Chicago, IL, USA) were used for statistical analysis. Categorical data are presented as frequencies and percentages. The categorical variables were analyzed using the Pearson's chi-square test. *P*-values  $\leq 0.05$  were considered statistically significant.

## Results

### *Annual distribution of pathogenic bacteria in clinical samples*

A total of 1942 patients treated at the burn ward of Zhejiang University of Medicine between January 2011 and December 2013 were included in this retrospective analysis, ranging from 1 to 97 years of age, including 1395 men and 547 women.

From cultures of burn patient wound secretions, respiratory secretions, catheter or main line samples, and blood, urine or stool samples, a total of 2212 strains of bacteria and fungi were identified. Of the 2212 strains identified, 750 (33.9%) were gram-positive bacteria, 1166 (52.7%) were gram-negative bacteria, and 296 (13.4%) were fungi (**Table 1**). Whilst there was no significant trend in the detection of gram-positive bacteria between 2011 and 2013, the fraction of gram-negative bacteria and fungi detected was significantly higher in 2012 than in 2011 and 2013 ( $P < 0.05$ , **Table 1**).

As illustrated in [Supplementary Table 1](#), gram-negative bacteria were most prevalent in urine culture, sputum culture, wound secretions and deep vein catheter culture. In sputum culture,

## Pathogen distribution and drug resistance in a burn ward

**Table 2.** Annual distribution of pathogens detected in clinical samples

Pathogen	2011		2012		2013			
	Strain (n)	Percentage (%)	Pathogen	Strain (n)	Percentage (%)	Pathogen	Strain (n)	Percentage (%)
<i>Staphylococcus aureus</i>	96	20.5	<i>Staphylococcus aureus</i>	86	16.6	<i>Staphylococcus aureus</i>	94	19.6
<i>Pseudomonas aeruginosa</i>	81	17.3	<i>Pseudomonas aeruginosa</i>	59	11.4	<i>Acinetobacter baumannii</i>	57	11.9
<i>Acinetobacter baumannii</i>	60	12.8	<i>Acinetobacter baumannii</i>	52	10.0	<i>Pseudomonas aeruginosa</i>	57	11.9
<i>Staphylococcus epidermidis</i>	31	6.6	<i>Escherichia coli</i>	28	5.4	<i>Escherichia coli</i>	30	6.3
<i>Escherichia coli</i>	21	4.4	<i>Klebsiella pneumoniae</i>	28	5.4	<i>Klebsiella pneumoniae</i>	27	5.6
<i>Klebsiella pneumoniae</i>	17	3.6	<i>Candida albicans</i>	26	5	<i>Staphylococcus epidermidis</i>	21	4.4
<i>Candida albicans</i>	16	3.4	<i>Staphylococcus epidermidis</i>	20	3.9	<i>Candida albicans</i>	20	4.2
<i>Proteus mirabilis</i>	15	3.2	<i>Enterococcus faecalis</i>	16	3.1	<i>Enterococcus faecalis</i>	17	3.5
<i>Candida tropicalis</i>	12	2.6	<i>Enterococcus faecium</i>	16	3.1	<i>Enterococcus faecium</i>	17	3.5
<i>Stenotrophomonas maltophilia</i>	12	2.6	<i>Staphylococcus haemolyticus</i>	16	3.1	<i>Enterobacter cloacae</i>	16	3.3
<i>Enterococcus faecalis</i>	11	2.3	<i>Candida albicans</i>	16	3.1	<i>Candida tropicalis</i>	11	2.3
<i>enterococcus faecium</i>	10	2.1	<i>Proteus mirabilis</i>	13	2.5	<i>Corynebacterium striatum</i>	11	2.3
<i>Enterobacter cloacae</i>	9	1.9	<i>Stenotrophomonas maltophilia</i>	13	2.5	<i>Proteus mirabilis</i>	11	2.3
<i>Candida glabrata</i>	6	1.3	<i>Candida glabrata</i>	12	2.3	<i>Stenotrophom Stenotrophomonas maltophilia</i>	11	2.3
<i>Staphylococcus haemolyticus</i>	5	1	<i>C.parapsilosis</i>	9	1.7	<i>Staphylococcus haemolyticus</i>	10	2.1

## Pathogen distribution and drug resistance in a burn ward

**Table 3.** Rate of resistance of Gram-positive bacteria to antibiotic drugs (%)

Antibiotic	<i>Staphylococcus epidermidis</i>			<i>Staphylococcus aureus</i>			<i>Enterococcus faecalis</i>			<i>Enterococcus faecium</i>		
	2011 (n=31)	2012 (n=20)	2013 (n=21)	2011 (n=96)	2012 (n=86)	2013 (n=94)	2011 (n=11)	2012 (n=17)	2013 (n=17)	2011 (n=10)	2012 (n=16)	2013 (n=17)
Methicillin	14.3	0	14.3	75.3	80.8	82.5	100	-	-	-	-	-
Oxacillin	80	94.7	80	76	81.2	86	100	-	-	-	-	-
Vancomycin	0	0	0	0	0	0	0	0	0	0	0	0
Linezolid	0	0	0	0	0	0	0	5.9	18.8	0	6.2	0
Teicoplanin	0	0	0	0	0	0	0	0	0	0	0	0
Clindamycin	66.7	55	66.7	58.9	67.4	83	100	100	100	100	100	100
Erythromycin	71.4	83.3	71.4	64.3	88	83	20	75	70	75	100	91.7
Ciprofloxacin	57.1	33.3	57.1	50	76	83	14.3	29.4	33.3	100	81.2	93.8

the proportion of gram-negative bacteria was as high as 85.7%, while the proportion of gram-positive bacteria was only 12.5%. Only in blood culture were more strains of gram-positive bacteria identified than strains of gram-negative bacteria.

The most frequently detected pathogens in wound secretions were *S. aureus*, *P. aeruginosa* and *A. baumannii* in 2011, 2012 and 2013 (Table 2). The gram-positive bacteria *Staphylococcus epidermidis*, *enterococcus faecalis* and *enterococcus faecium* were also among the ten most frequently detected bacteria each year, and the gram-negative bacteria *Escherichia coli*, *Klebsiella pneumoniae*, *Enterobacter cloacae*, *Stenotrophomonas maltophilia*, *Proteus mirabilis* were also frequently detected (Table 2). The most frequently detected strains of fungi were *Candida albicans* and *Candida tropicalis* (Table 2).

### Antibiotic resistance

The susceptibility of isolated bacteria and fungi to commonly used antibiotic or antifungal drugs was investigated (Tables 3-5). As indicated in Table 3, a minority of *S. epidermidis* isolates (0 to 14.3%) was resistant to methicillin (MRSE), but a majority of *S. aureus* isolates (75.3 to 82.5%) were resistant to methicillin (MRSA). No *S. aureus*, *Enterococcus faecalis* or *Enterococcus faecium* isolates were resistant to the glycopeptide antibiotic vancomycin. No *S. aureus* isolates were resistant to the oxazolidinone linezolid or the glycopeptide teicoplanin, but most *S. aureus* isolates were resistant to the narrow-spectrum beta-lactam antibiotic oxacillin, the lincosamide Clindamycin, the macrolide erythromycin and the second-generation fluoroquinolone ciprofloxacin. In 2011 all *E. faeca-*

*lis* isolates were resistant to the beta-lactam antibiotic oxacillin, but no other *E. faecalis* or *E. faecium* isolates were tested for oxacillin resistance. All *E. faecalis* and *E. faecium* isolates were resistant to clindamycin and most were resistant to erythromycin and ciprofloxacin (Table 3).

As illustrated in Table 4, of the five most commonly isolated strains of gram-negative bacteria, fewer *P. aeruginosa* isolates were resistant to amikacin, ciprofloxacin and ceftazidime. However more gram-negative isolates were resistant to carbon penicillin drugs such as imipenem and meropenem, and ceftriaxone and cefotaxime, while few were resistant to enzyme inhibitor complex antibiotics, such as cefoperazone/sulbactam or piperacillin/tazobactam. 8% of gram-negative isolates were resistant to polymyxin B in 2011, but no polymyxin B resistance was detected in 2012 or 2013. *A. baumannii* isolates were mostly resistant to carbapenem, aminoglycoside, cephalosporin, enzyme inhibitor complex antibiotics, fluoroquinolones and other antibiotics. No resistance to polymyxin B was detected in 2011 and 2012, but 2% of strains isolated in 2013 were resistant to this antibiotic. *K. pneumoniae* isolated were often resistant to aminoglycoside, cephalosporin, enzyme inhibitor complex antibiotics, fluoroquinolones and other antibiotics, and between 21.7% and 63% of isolates were resistant to carbapenem antibiotics. Many *E. coli* isolates were resistant to cephalosporins and quinolones, while few were resistant to enzyme inhibitor complex antibiotics such as piperacillin/tazobactam and cefoperazone/sulbactam, carbon penicillins or amikacin. No resistance to polymyxin B was detected. Between 25% and 42.9% *Proteus mirabilis* iso-

## Pathogen distribution and drug resistance in a burn ward

**Table 4.** Rate of resistance of Gram-negative bacteria to antibiotic drugs (%)

Bacteria/year Antibiotic	<i>Pseudomonas aeruginosa</i>			<i>Acinetobacter baumannii</i>			<i>Klebsiella pneumoniae</i>			<i>Escherichia coli</i>			<i>Proteus mirabilis</i>		
	2011 (n=81)	2012 (n=59)	2013 (n=57)	2011 (n=60)	2012 (n=52)	2013 (n=57)	2011 (n=17)	2012 (n=28)	2013 (n=27)	2011 (n=21)	2012 (n=28)	2013 (n=30)	2011 (n=15)	2012 (n=13)	2013 (n=11)
Imipenem	70	17.2	41.8	89.7	84.6	82.5	41.2	32.1	63	0	7.1	3.3	0	60	88.9
Meropenem	64.5	18.2	36.5	83.8	62.5	80.4	33.3	21.7	54.2	0	0	0	0	8.3	0
Ertapenem	-	-	-	-	-	-	41.2	34.8	59.1	0	11.1	3.8	0	0	0
Amikacin	48.8	13.6	23.2	55.9	38.5	35.1	23.5	14.3	55.6	14.3	7.1	16.7	6.7	7.7	0
Gentamicin	55	20.3	46.4	86.4	80.8	75.4	35.3	60.7	63	66.7	71.4	63.3	46.7	23.1	18.2
Tobramycin	57.4	12.3	20	72.9	80.8	75.4	35.7	25	55.6	42.9	35.7	36.7	38.5	7.7	9.1
Ceftazidime	35.3	16.4	30.9	84.5	87	87.8	50	63	75	76.2	69.2	70.8	42.9	33.3	25
Ampicillin	100	100	100	100	100	100	100	100	100	94.4	92.9	93.3	66.7	46.2	36.4
Ampicillin/Sulbactam	97.2	96.4	100	89.1	84.8	93.3	58.8	59.3	80	78.9	69.2	100	30.8	50	-
Piperacillin/Tazobactam	64	22	46.3	89.7	84.3	82.5	41.2	35.7	63	15	3.6	13.3	6.7	0	0
Aztreonam	64.9	41.4	47.4	100	92.3	96.5	56.2	64.3	77.8	76.2	66.7	76.7	40	30.8	36.4
Levofloxacin	35.9	11.9	14	65	57.7	57.9	52.9	21.4	59.3	81	44.4	66.7	53.3	23.1	9.1
Ciprofloxacin	23.1	10.7	20	87.9	86.5	82.5	58.8	22.2	59.3	81	50	70	64.3	30.8	27.3
Polymyxin B	2.8	0	0	0	0	2	0	0	0	0	0	0	100	-	100
Tigecycline	-	-	-	-	-	-	-	0	-	-	0	-	-	-	-
Cefoperazone/Sulbactam	63.5	19.1	41.8	74.3	63	70.9	33.3	66.7	65.4	0	0	13.6	0	0	0
Cefuroxime	-	100	-	83.3	100	-	50	60	80	80	70	100	55.6	66.7	-
Cefepime	65	24.6	40.4	90	86.5	82.5	52.9	64.3	77.8	76.2	64.3	73.3	40	30.8	36.4
Cefotaxime	74.3	61.2	72.1	92.1	90.9	93.8	60	60	80	75	66.7	100	40	33.3	-
Ceftriaxone	73.1	60.3	68.4	95.6	98	84.2	58.3	65.2	77.8	75	66.7	69.8	40	30	36.4

(-) drug susceptibility was not performed.



## Pathogen distribution and drug resistance in a burn ward

**Table 5.** Rate of resistance of isolated fungi to antifungal drugs (%)

Antifungal Agents	2011 (n=41)	2012 (n=77)	2013 (n=43)
Amphotericin B	3.1	5.5	2.3
Itraconazole	4.5	3.6	0, 0
Ketoconazole	50	56.2	38.1
Fluconazole	2	6.7	4.9
Miconazole	3.6	5.6	3.2
Clotrimazole	0	11.1	18.6
Nystatin	0	3.9	0, 0

lates were resistant to cephalosporin drugs, but few isolates were resistant to enzyme inhibitor complex antibiotics such as piperacillin/tazobactam and cefoperazone/sulbactam, amikacin, carbon penicillin such as meropenem and ertapenem. Surprisingly, 60% and 88.9% of isolates were resistant to imipenem in 2012 and 2013, respectively. Resistance of *Proteus mirabilis* to quinolones declined during this period, however all isolates were resistant to polymyxin B in 2012 and 2013.

*Candida albicans*, *tropicalis*, *glabrata* and *parapsilosis* are highly sensitive to itraconazole, fluconazole and voriconazole, but were commonly resistant to ketoconazole (Table 5). Few fungal isolates were resistant to amphotericin B, nystatin or itraconazole, but many were resistant to ketoconazole.

### Discussion

Understanding the distribution of bacterial infections in Chinese hospitals will be crucial for the development of treatment guidelines designed to reduce hospital-acquired infection and drug resistance. In this study, we characterized the pathogenic infections of a large sample of 1942 inpatients of the burn ward of the second affiliated hospital of Zhejiang University of Medicine between 2011 and 2013. In total 2212 strains of pathogenic bacteria or fungi were cultured from wound secretions, blood, catheter swabs, respiratory secretions, urine and stool. Of the 2212 strains identified, 33.9% were gram-positive bacteria, 52.7% were gram-negative bacteria, and 13.4% were fungi. Gram-negative bacteria were most prevalent in urine culture, sputum culture, wound secretions and deep vein catheter culture. Only in blood culture were more strains of

gram-positive bacteria identified than strains of gram-negative bacteria.

The most frequently detected pathogens in wound secretions were *S. aureus*, *Ps aeruginosa* and *A. baumannii* each year. The gram-positive bacteria *S. epidermidis*, *Enterococcus faecalis* and *Enterococcus faecium*, and the gram-negative bacteria *Escherichia coli*, *K. pneumoniae*, *E. cloacae*, *S. maltophilia*, *Proteus mirabilis* were also frequently detected. The most frequently detected strains of fungi were *Candida albicans* and *tropicalis*.

Within the three-year period of study no significant trends in pathogen distribution were observed, and our findings were in line with similar studies at other hospitals in China and abroad. A previous, smaller study of 492 inpatients treated for burns at the Jishuitan Hospital between 2003 and 2005 found a higher proportion of gram-negative bacteria in cultures of wound secretions [33]. 54.5% of the pathogens identified in that study were gram-negative bacteria, and 42.8% were gram-positive bacteria. In their samples the most frequently detected bacteria were *S. aureus* (16.9%), *P. aeruginosa* (12.5%), and the most frequently detected gram-negative bacteria were *P. aeruginosa*, *E. coli*, *A. baumannii*, *E. cloacae* and *K. pneumoniae*. Similarly in culture of wound secretions from Swiss ICU patients between 1986 and 2005 *S. aureus* was also the most frequently identified pathogen, accounting for 20.8% of all isolates, followed by *E. coli* (13.9%), *P. aeruginosa* (11.8%), coagulase negative *Staphylococcus* (10.9%), enterococcus (9.7%), *E. cloacae* (5.6%), *K. pneumoniae* (5%), *Acinetobacter* (3.2%), *Proteus mirabilis* (2%), and *S. maltophilia* (1.4%) [3]. In a sample of children suffering from burns at a hospital in Tehran between 2005 to 2009, 66.8% of wound secretions were found to be *Staphylococcus* positive, and 12% of blood cultures contained *P. aeruginosa* [34]. Within the three-year period of study no significant trends in bacterial or fungal drug resistance were observed. Gram-positive isolates included both MRSA and methicillin-sensitive *S. aureus* (MSSA) and both MRSE and methicillin-sensitive *S. epidermidis* (MSSE). The rate of *S. aureus* methicillin resistance peaked at about 80%, lower than that detected at a burn center of Southwest Hospital [35], but higher than that detected at Shanghai Ruijin Hospital in 2003 [36].

## Pathogen distribution and drug resistance in a burn ward

Of the gram-positive bacteria detected, five and 11 strains of *Corynebacterium striatum* were detected in our department in 2012 and 2013, respectively, including samples collected from one patient in septic shock. Between 2004 and 2005, 36 strains of *C. striatum* were isolated in our hospital, indicating that this problem may be declining in our hospital [35]. *C. striatum* is a non-spore-forming gram-positive corynebacterium and considered to be a hyperparasite of the surface of skin or mucosa. Long-term bedridden and immunocompromised patients are susceptible to septicemia induced by *C. striatum* [36]. The CLSI lacks interpretive standards of susceptibility for non-spore forming gram-positive corynebacterium, but our screening revealed that isolated *C. striatum* was sensitive to Vancomycin, Teicoplanin and Imipenem, while less sensitive to quinolones, sulfonamides, macrolide and other antibiotics [35, 37].

Although it may seem strange that the wound secretions were dominated by gram-negative bacteria, while the blood culture was dominated by gram-positive bacteria, this trend has been previously reported by Karimi *et al.* who found that coagulase-negative staphylococci dominated in wounds, while *P. aeruginosa* dominated in the blood [34], and Chim *et al.*, reported that *A. baumannii*, MRSA and *P. aeruginosa*, dominated in the wound while coagulase-negative staphylococci dominated in the blood [38]. These observed differences may result from the different collection times of wound secretions and blood culture specimen. In wound secretions *S. aureus*, *P. aeruginosa* and *A. baumannii* were detected most frequently in all three years of our study, consistent with previous reports [38, 39]. Keen *et al.* also reported that *A. baumannii*, *P. aeruginosa* and *K. pneumoniae* were most frequently detected [40]. An eight-year study published by Feng *et al.* found the most frequent hospital infections to be *P. aeruginosa*, *S. aureus* and *Candida* [41], and Bayram *et al.* found that in a 3-year survey the most frequently detected pathogens were *A. baumannii*, coagulase-negative staphylococci and *P. aeruginosa* [42].

Detected coagulase-negative staphylococci included *S. epidermidis* and *Staphylococcus saprophyticus*, both typically part of the normal flora of skin and mucous membranes [43]. *S. epidermidis* can cause prosthetic valve endo-

carditis, venous catheter infection, peritonitis, vessel-related infection and artificial joint infection, while *S. saprophyticus* is the main pathogen responsible for urinary tract infection in women [44]. The other types of coagulase-negative staphylococci also have become important opportunistic pathogens of patients with impaired immune function.

*Proteus mirabilis* and *vulgaris* can induce primary and secondary infection in human, and are also commonly responsible for urinary system infection. *Acinetobacter* is an opportunistic pathogen found in the skin follicle, respiratory tract, and the environment. In a warm environment, *Acinetobacter* often colonizes wounds producing nosocomial infections. In recent years, studies have shown that *A. baumannii* is a prevalent pathogenic bacterium, and is often resistant to multiple antibiotic drugs.

Wet burn wounds coupled with long hospital stays, long-term administration of broad-spectrum antibiotics, delayed wound processing and prolonged invasive procedures provide a favorable niche for development of multiply drug resistant strains of *P. aeruginosa*. *P. aeruginosa* has been demonstrated to evade antibiotic therapy via mutations in the efflux system and outer membrane proteins, production of inactivating enzymes such as lactamase, and bacterial biofilm formation [45-47].

We found low rates of meropenem and amikacin resistance in *P. aeruginosa*, however the rates of resistance were higher than in previous reports [39, 41, 48]. *A. baumannii* was highly resistant to third generation cephalosporins such as ceftazidime, carbapenem and other antibiotics, but highly sensitive to polymyxin B. Gram-negative bacteria were sensitive to tigecycline (a glycylcine antibiotic derivative of minocycline), whereas *P. aeruginosa* is naturally resistant to this class of antibiotics [49]. *Enterobacteriaceae*, *K. pneumoniae* and *P. mirabilis* resistant to Carbapenem appeared in the last 2 years, and only *E. coli* remained highly sensitive. In vitro studies of tigecycline have demonstrated efficacy against *A. baumannii*, *Enterobacter* and MRSA [50].

We found *K. pneumoniae* had a similar resistance profile with *A. baumannii* and *P. aeruginosa*. Resistance of *K. pneumoniae* is worthy of further attention. Our findings confirm previous



## Pathogen distribution and drug resistance in a burn ward

reports that multi-drug resistant *A. baumannii*, ESBL-producing Enterobacteriaceae and carbapenem-resistant *P. aeruginosa* pose major problems for the treatment of gram-negative bacterial infections [42, 51].

*S. aureus* was among the first pathogen detected in wound secretions, and *S. epidermidis* was also rapidly prevalent in wounds. These bacteria are sensitive to glycopeptide antibiotics, and no resistant strains of *S. epidermidis* were found, however a majority of *S. aureus* isolates were methicillin-resistant, a far higher rate than reported elsewhere [20, 42].

We identified a higher rate of fungal pathogens in 2012 than 2011 and 2013. Specifically, *Candida albicans*, *tropicalis*, *glabrata* and *parapsilosis* were prevalent. These isolates were highly sensitive to itraconazole, fluconazole and voriconazole with a rate of resistance under 10%, while resistance to ketoconazole was more prevalent. Fungi were most prevalent in urine cultures. Further investigation will be required to determine the impact of patient age, antibiotic administration, sedentary lifestyle during hospitalization and long-term catheterization on for these high rates of infection.

In addition to local treatment of burn wounds and systemic antibiotic therapy, our center has adopted a bundle of hospital infection control measures. The cross-infection control measures currently applied in our department include nursing procedures, aseptic procedures, hand hygiene, disinfection and isolation, ward flow control, microbial monitoring and regular replacement of deep venous catheter location. Before 2012, patients were treated according to the guidelines of the *Diagnostic Criteria for Infection after Burn Injury* (Chinese Journal of Burns, 2007) [33]. Our center conducts regular bacteriological monitoring of severe burn patients to ensure targeted medication, and ensures rapid application of tailored therapy. Antibiotic drugs were selected based on experience prior to identifying pathogens. The principle of “de-escalation” was adopted in antibiotic administration, stressing “early use, early stop” and “perioperative application”. Antibiotics were applied to wounds, or administered systemically when they could not be applied to burn wound. Similar guidelines or strategies have been followed worldwide [20, 50, 52].

The Southwest Hospital Affiliated to Third Military Medical University reported that the detection rate of MRSA was gradually decreasing, and resistance to clindamycin, erythromycin and other macrolide drugs also declined [39, 41]. In this survey, the detection rate of MRSA and rates of resistance to clindamycin and erythromycin increased over the three-year study period, while resistance of *P. aeruginosa* to ciprofloxacin, levofloxacin and other fluoroquinolones remained relatively low. Westh *et al.* reported that resistance against macrolides was associated with usage of quinolones [53].

### Limitations

This retrospective study only included data from patients treated at one site, and did not record patient clinical or demographic characteristics. The timespan of three years was too short to allow any trends in pathogen diversity or antibiotic or antifungal resistance to be defined. No samples were retained for more in-depth molecular identification and homology analysis, and as specimens were collected after hospitalization we could not differentiate between environmental community-acquired or hospital-acquired infection.

### Conclusions

In this study, we characterized the pathogenic infections of 1942 inpatients of the burn ward of the second affiliated hospital of Zhejiang University of Medicine between 2011 and 2013. In total 2212 strains of pathogenic bacteria or fungi were cultured from wound secretions, blood, catheter specimens, respiratory secretions, urine and stool. Their sensitivity to commonly used antibiotic and antifungal drugs was retrospectively analyzed. Of the 2212 strains identified, 33.9% were gram-positive bacteria, 52.7% were gram-negative bacteria, and 13.4% were fungi. Gram-positive bacteria mainly included *S. aureus*, *S. epidermidis* *Enterococcus*, gram-negative bacteria mainly included *P. aeruginosa*, *A. baumannii*, *K. pneumoniae* and *E. coli*, while fungi mainly included *C. albicans* and *tropicalis*. Understanding the distribution of bacterial infections in Chinese hospitals will be crucial for the development of treatment guidelines designed to reduce hospital-acquired infection and reduce drug resistance. In-depth attention should be paid to proportion of MRSA, multi-resistant *A. baumannii*,

## Pathogen distribution and drug resistance in a burn ward

ESBL-producing enterobacteriaceae and Carbapenem-resistant *P. aeruginosa*.

### Acknowledgements

Thanks to Rong Zhang, director of bacteriology room for the support.

### Disclosure of conflict of interest

None.

**Address correspondence to:** Hanghui Cen, Department of Burns, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou 310000, Zhejiang, China. Tel: +86-13757119579; Fax: +86-10-55499227; E-mail: 593520985@qq.com

### References

- [1] Wang Y, Tang HT, Xia ZF, Zhu SH, Ma B, Wei W, Sun Y and Lv KY. Factors affecting survival in adult patients with massive burns. *Burns* 2010; 36: 57-64.
- [2] Ansermino M and Hemsley C. Intensive care management and control of infection. *BMJ* 2004; 329: 220-223.
- [3] Guggenheim M, Zbinden R, Handschin AE, Gohritz A, Altintas MA and Giovanoli P. Changes in bacterial isolates from burn wounds and their antibiograms: a 20-year study (1986-2005). *Burns* 2009; 35: 553-560.
- [4] Hodle AE, Richter KP and Thompson RM. Infection control practices in U.S. burn units. *J Burn Care Res* 2006; 27: 142-151.
- [5] Santucci SG, Gobara S, Santos CR, Fontana C and Levin AS. Infections in a burn intensive care unit: experience of seven years. *J Hosp Infect* 2003; 53: 6-13.
- [6] Giske CG, Monnet DL, Cars O and Carmeli Y. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. *Antimicrob Agents Chemother* 2008; 52: 813-821.
- [7] Manson WL, Pernot PC, Fidler V, Sauer EW and Klasen HJ. Colonization of burns and the duration of hospital stay of severely burned patients. *J Hosp Infect* 1992; 22: 55-63.
- [8] Vindenes H and Bjerknes R. Microbial colonization of large wounds. *Burns* 1995; 21: 575-579.
- [9] Sharma BR. Infection in patients with severe burns: causes and prevention thereof. *Infect Dis Clin North Am* 2007; 21: 745-759, ix.
- [10] Magnotti LJ and Deitch EA. Burns, bacterial translocation, gut barrier function, and failure. *J Burn Care Rehabil* 2005; 26: 383-391.
- [11] Soares de Macedo JL and Santos JB. Nosocomial infections in a Brazilian Burn Unit. *Burns* 2006; 32: 477-481.
- [12] Ahuja RB, Gupta A and Gur R. A prospective double-blinded comparative analysis of framycetin and silver sulphadiazine as topical agents for burns: a pilot study. *Burns* 2009; 35: 672-676.
- [13] Vindenes HA, Ulvestad E and Bjerknes R. Concentrations of cytokines in plasma of patients with large burns: their relation to time after injury, burn size, inflammatory variables, infection, and outcome. *Eur J Surg* 1998; 164: 647-656.
- [14] Alexander M, Chaudry IH and Schwacha MG. Relationships between burn size, immunosuppression, and macrophage hyperactivity in a murine model of thermal injury. *Cell Immunol* 2002; 220: 63-69.
- [15] Church D, Elsayed S, Reid O, Winston B and Lindsay R. Burn wound infections. *Clin Microbiol Rev* 2006; 19: 403-434.
- [16] Oncul O, Ulkur E, Acar A, Turhan V, Yeniz E, Karacaer Z and Yildiz F. Prospective analysis of nosocomial infections in a burn care unit, Turkey. *Indian J Med Res* 2009; 130: 758-764.
- [17] Kumar A, Kashyap B, Mishra S, Agarwal V and Kaur IR. Bacteriological analysis and antibacterial resistance pattern in burn sepsis: An observation at a tertiary care hospital in east Delhi. *Infect Dis Clin Pract* 2011; 19: 406-412.
- [18] Mayhall CG. The epidemiology of burn wound infections: then and now. *Clin Infect Dis* 2003; 37: 543-550.
- [19] Rastegar Lari AR, Alaghebandan R and Akhlaghi L. Burn wound infections and antimicrobial resistance in tehran, iran: an increasing problem. *Ann Burns Fire Disasters* 2005; 18: 68-73.
- [20] Avni T, Levkovich A, Ad-El DD, Leibovici L and Paul M. Prophylactic antibiotics for burns patients: systematic review and meta-analysis. *BMJ* 2010; 340: c241.
- [21] Shelby J and Merrell SW. In vivo monitoring of postburn immune response. *J Trauma* 1987; 27: 213-216.
- [22] Singh D, Singh A, Sharma AK and Sodhi L. Burn mortality in Chandigarh zone: 25 years autopsy experience from a tertiary care hospital of India. *Burns* 1998; 24: 150-156.
- [23] Sharma BR, Harish D, Singh VP and Bangar S. Septicemia as a cause of death in burns: an autopsy study. *Burns* 2006; 32: 545-549.
- [24] Taneja N, Emmanuel R, Chari P and Sharma M. A prospective study of hospital-acquired infections in burn patients at a tertiary care referral centre in North India. *Burns* 2004; 30: 665-669.

## Pathogen distribution and drug resistance in a burn ward

- [25] Azimi L, Motevallian A, Ebrahimzadeh Namvar A, Asghari B and Lari AR. Nosocomial infections in burned patients in motahari hospital, tehran, iran. *Dermatol Res Pract* 2011; 2011: 436952.
- [26] Özkurt Z, Altoparlak Ü, Yilmaz SI, Erol S, Özden K and Akçay MN. Reducing hospital infection rates in the burn unit by adherence to infection control measures: a six-year experience. *Turkish Journal of Medical Sciences* 2012; 42: 17-24.
- [27] Bayat A, Shaaban H, Dodgson A and Dunn KW. Implications for Burns Unit design following outbreak of multi-resistant *Acinetobacter* infection in ICU and Burns Unit. *Burns* 2003; 29: 303-306.
- [28] Shi MM, Zhao DM, Wang Q, Cheng J, Ma T, Xu YH, Xu QL and Li JB. [Analysis of drug resistance and risk factors of Enterobacteriaceae in burn units]. *Zhonghua Shao Shang Za Zhi* 2010; 26: 199-201.
- [29] Zorgani A, Franka RA, Zaidi MM, Alshweref UM and Elgmati M. Trends in nosocomial bloodstream infections in a burn intensive care unit: an eight-year survey. *Ann Burns Fire Disasters* 2010; 23: 88-94.
- [30] Li C, Ren N, Wen X, Zhou P, Huang X, Gong R, Lv Y, Feng L, Wu H, Liu Z, Fu C, Huang X, Li J, Chen Y, Zeng C, Zuo S, Xiong X, Xu X and Wu A. Changes in antimicrobial use prevalence in China: results from five point prevalence studies. *PLoS One* 2013; 8: e82785.
- [31] Tao XB, Qian LH, Li Y, Wu Q, Ruan JJ, Cai DZ and Peng H. Hospital-acquired infection rate in a tertiary care teaching hospital in China: a cross-sectional survey involving 2434 inpatients. *Int J Infect Dis* 2014; 27: 7-9.
- [32] Peng Y and Yuan Z. Diagnostic Criteria for Infection after Burn Injury. *Zhonghua Shao Shang Za Zhi* 2007; 23: 404-405.
- [33] Li M, Zhang GA and Liu Y. [Analysis of predominant bacteria of burn infection and their resistance to antibiotics in recent years]. *Zhonghua Shao Shang Za Zhi* 2007; 23: 91-93.
- [34] Karimi H, Montevalian A, Motabar AR, Safari R, Parvas MS and Vasigh M. Epidemiology of paediatric burns in Iran. *Ann Burns Fire Disasters* 2012; 25: 115-120.
- [35] Ma JH, Peng ZY, Xu ZJ and Zhang R. Analysis of the activity of 13 antibiotics against *Corynebacterium striatum* in vitro. *Laboratory Medicine* 2007; 22: 383-384.
- [36] Tarr PE, Stock F, Cooke RH, Fedorko DP and Lucey DR. Multidrug-resistant *Corynebacterium striatum* pneumonia in a heart transplant recipient. *Transpl Infect Dis* 2003; 5: 53-58.
- [37] Sierra JM, Martinez-Martinez L, Vazquez F, Giralt E and Vila J. Relationship between mutations in the *gyrA* gene and quinolone resistance in clinical isolates of *Corynebacterium striatum* and *Corynebacterium amycolatum*. *Antimicrob Agents Chemother* 2005; 49: 1714-1719.
- [38] Chim H, Tan BH and Song C. Five-year review of infections in a burn intensive care unit: High incidence of *Acinetobacter baumannii* in a tropical climate. *Burns* 2007; 33: 1008-1014.
- [39] Peng DZ, Liu XL, Liu ZY, Shu WT, Zhou X, Liu J, Huang YS, Wu J and Fu WL. [Analysis of distribution characteristics and drug resistance of 2748 strains of pathogens isolated from burn patients]. *Zhonghua Shao Shang Za Zhi* 2012; 28: 87-95.
- [40] Keen EF 3rd, Robinson BJ, Hospenthal DR, Aldous WK, Wolf SE, Chung KK and Murray CK. Incidence and bacteriology of burn infections at a military burn center. *Burns* 2010; 36: 461-468.
- [41] Sun FJ, Zhang XB, Fang Y, Chen J, Xing H, Shi H, Feng W and Xia P. Spectrum and drug resistance of pathogens from patients with burns. *Burns* 2012; 38: 1124-1130.
- [42] Bayram Y, Parlak M, Aypak C and Bayram I. Three-year review of bacteriological profile and antibiogram of burn wound isolates in Van, Turkey. *Int J Med Sci* 2013; 10: 19-23.
- [43] Becker K, Heilmann C and Peters G. Coagulase-negative staphylococci. *Clin Microbiol Rev* 2014; 27: 870-926.
- [44] Mirone V and Franco M. Clinical aspects of antimicrobial prophylaxis for invasive urological procedures. *J Chemother* 2014; 26 Suppl 1: S1-S13.
- [45] Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S and Carmeli Y. Multidrug-resistant *Pseudomonas aeruginosa*: risk factors and clinical impact. *Antimicrob Agents Chemother* 2006; 50: 43-48.
- [46] Armour AD, Shankowsky HA, Swanson T, Lee J and Tredget EE. The impact of nosocomially-acquired resistant *Pseudomonas aeruginosa* infection in a burn unit. *J Trauma* 2007; 63: 164-171.
- [47] Suber F, Carroll MC and Moore FD Jr. Innate response to self-antigen significantly exacerbates burn wound depth. *Proc Natl Acad Sci U S A* 2007; 104: 3973-3977.
- [48] Rezaei E, Safari H, Naderinasab M and Aliakbarian H. Common pathogens in burn wound and changes in their drug sensitivity. *Burns* 2011; 37: 805-807.
- [49] Leseva M, Arguirova M, Nashev D, Zamfirova E and Hadzhyiski O. Nosocomial infections in burn patients: etiology, antimicrobial resistance, means to control. *Ann Burns Fire Disasters* 2013; 26: 5-11.
- [50] Timurkaynak F, Arslan H, Azap OK, Senger SS, Basaran O, Karaman SO and Haberal M. In vi-

## Pathogen distribution and drug resistance in a burn ward

- tro activity of tigecycline against resistant micro-organisms isolated from burn patients. *Burns* 2008; 34: 1033-1036.
- [51] Fadeyibi IO, Raji MA, Ibrahim NA, Ugburo AO and Ademiluyi S. Bacteriology of infected burn wounds in the burn wards of a teaching hospital in Southwest Nigeria. *Burns* 2013; 39: 168-173.
- [52] Ubbink DT, Santema TB and Stoekenbroek RM. Systemic wound care: a meta-review of cochrane systematic reviews. *Surg Technol Int* 2014; 24: 99-111.
- [53] Westh H, Zinn CS and Rosdahl VT. An international multicenter study of antimicrobial consumption and resistance in *Staphylococcus aureus* isolates from 15 hospitals in 14 countries. *Microb Drug Resist* 2004; 10: 169-176.

## Pathogen distribution and drug resistance in a burn ward

**Supplementary Table 1.** Annual distribution of Gram-positive and negative bacteria and fungi detected in clinical samples

Year	Strains identified (n)	Gram-positive bacteria [n (%)]	Gram-negative bacteria [n (%)]	Fungi [n (%)]
Wound Secretion Culture				
2011	468	168 (35.9)	259 (55.3)	41 (8.8)
2012	518	188 (36.3)	253 (48.8)	77 (14.9)
2013	480	187 (39)	250 (52.1)	43 (8.9)
Sputum Culture				
2011	56	9 (16.1)	46 (82.1)	1 (1.8)
2012	41	10 (24.4)	30 (73.2)	1 (2.4)
2013	56	7 (12.5)	48 (85.7)	1 (1.8)
Urine Culture				
2011	100	13 (13)	62 (2)	25 (25)
2012	116	22 (19)	38 (32.8)	56 (48.2)
2013	119	27 (22.7)	59 (49.6)	33 (27.7)
Stool Culture				
2011	2	0 (0)	1 (50)	1 (50)
2012	3	0 (0)	0 (0)	3 (100)
2013	0	0 (0)	0 (0)	0 (0)
Blood Culture				
2011	49	26 (53)	22 (44.9)	1 (1.1)
2012	35	20 (57.1)	12 (34.3)	3 (8.6)
2013	44	23 (52.3)	20 (45.5)	1 (2.2)
Deep vein catheter culture				
2011	48	19 (39.6)	27 (56.3)	2 (4.1)
2012	37	17 (46)	16 (43)	4 (11)
2013	40	14 (35)	23 (57.5)	3 (7.5)